DexCom Inc
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3032% below fair value
$80.19−2.33 (-2.82%)
Close on Nov 19, 2026Market cap $29.91BP/E 31.6Yield –
DexCom Share-Based Compensation by Quarter
Share-Based Compensation — Selling, General & Administrative ($M)
DexCom Share-Based Compensation: $23.8M in Q3 2026, down 25.4% from a year earlier.
Latest, Q3 2026
23.8
Period ended Sep 30, 2026
Change on a year earlier
-25.4%
31.9 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
32
Documents cited below
Where the Q3 2026 figure comes from
Source: 10-Q (FY2026Q3, filed 2026-10-29) ↗
Reported in Form 10-K & Form 10-Q Footnotes (XBRL).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). DexCom Share-Based Compensation ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from DexCom SEC filings and investor materials. https://stockdatahq.com/stocks/dxcm/kpis/sbc-alloc-sga
See every metric in the DexCom KPI table. Data updated Nov 7, 2026.
See a number that looks wrong?